Birinapant (TL32711)

DRUG2 trials

Sponsors

TetraLogic Pharmaceuticals, National Cancer Institute (NCI)

Conditions

CancerEpithelial Ovarian CancerFallopian Tube NeoplasmsPeritoneal Neoplasms

Phase 1

Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

CompletedNCT00993239

TetraLogic PharmaceuticalsCancer

Start: 2009-11-30End: 2013-03-31Updated: 2016-03-03

Phase 2

Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer

TerminatedNCT01681368

National Cancer Institute (NCI)Epithelial Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Neoplasms

Start: 2012-08-15End: 2014-04-30Updated: 2017-05-30

Related Papers

Pharmacodynamic biomarkers from phase II study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-mimetic birinapant (TL32711; NSC 756502) in relapsed platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC) (NCT01681368).

Journal of Clinical Oncology2014-05-204 citations